|
Found 111 result(s) FROM 1963 pages containing the term 'psoriatic spondyloarthritis'.
Tuesday Oct 06, 2009
Simponi Scores EU OK for RA, PsA, AS
Simponi (golimumab) anti-TNF is the first monthly anti-TNF injectable to gain broad EU approval...
Tuesday Jun 16, 2009
Golimumab for Psoriatic Arthritis Still Effective at 2 Years
2-Year GO-REVEAL data show durable PsA response to golimumab...
Friday May 22, 2009
Johnson & Johnson Wants Remicade Back
J&J is going to court to end its Remicade partnership with Schering-Plough due to a merger with Merck...
Wednesday Apr 29, 2009
Simponi Approved in US for RA, PsA, AS
The US Food and Drug Administration this week joined Canada's drugs agency in approving Simponi (golimumab) for moderate to severe RA, active PsA, and active ankylosing spondylitis...
Tuesday Apr 14, 2009
Golimumab Gets Canadian OK for RA, PsA, AS
Health Canada has approved Centocor's Simponi (golimumab) for treatment of moderately to severely active rheumatoid arthritis (RA), active psoriatic arthritis (PsA), and active ankylosing spondylitis (AS)...
Tuesday Apr 07, 2009
Low Back, Limb Pain May Be Early Spondyloarthritis
Low back pain, sacroiliitis, and limb arthritis are all early signs of spondyloarthritis...
Wednesday Feb 18, 2009
Ustekinumab Reduces Psoriatic Arthritis Pain, Clears Lesions
Ustekinumab (CNTO 1275), a new monoclonal antibody that blocks interleukin (IL)-12 and IL-23 (IL-23), may help thwart the pain, swelling and lesions of psoriatic arthritis...
Tuesday Nov 18, 2008
Centocor's Golimumab Gives Durable Skin, Joint Relief in Psoriatic Arthritis, ACR Studies Say
More than half of active psoriatic arthritis patients receiving subcutaneous injections of 50 mg or 100 mg of golimumab (CNTO 148) every 4 weeks showed improvements that lasted through 1 year in the joint and skin symptoms...
Wednesday Oct 08, 2008
Incyte's Topical JAK Inhibitor Shows Positive Proof-of-Concept Results in Two Phase IIa Clinical Trials in Patients with Mild-to-Moderate Psoriasis; Phase IIb Expected to Start October 2008
Results from the first study demonstrated that INCB18424 was well tolerated at all doses and significantly improved overall total lesion score (erythema + scaling + thickness)...
Monday Sep 29, 2008
Abbott Reports Continuous Treatment With Humira® Achieves Superior Long-Term Efficacy for Psoriasis Patients in the US and Europe Versus Interrupting Treatment
The findings were from the company's pivotal 52-week REVEAL study and the period of open-label treatment that followed...
Tuesday Aug 26, 2008
After Fits and Starts, New Hope for Psoriasis Patients
Psoriasis patients are finally finding some relief with a new wave of drug treatments known as biologics…
Thursday Jul 17, 2008
Classification and Categorization of Psoriatic Arthritis
Researchers in the field of psoriatic arthritis are working to overhaul Moll and Wright’s criteria for the classification and categorization of the disease…
Tuesday Jul 15, 2008
Wyeth Reports European Commission Announces Marketing Authorization for 50 mg Once-Weekly Enbrel® (etanercept) for Patients With Moderate-to-Severe Psoriasis
The European Commission announced a new 50 mg Enbrel® (etanercept) once-weekly dosage regimen as an alternative to the currently approved 25 mg Enbrel twice-weekly regimen for the treatment of moderate-to-severe plaque psoriasis...
Thursday Jul 10, 2008
Merck Serono Reports EMEA Confirms Positive Benefit-Risk Balance With Raptiva® for the Treatment of Psoriasis; European Commission Approved Product Information Update to Include Data on Up to 3 Years of Treatment
The European Commission has approved an update of the Summary of Product Characteristics (SPC) for Raptiva® (efalizumab) in the treatment of moderate-to-severe chronic plaque psoriasis...
Thursday Jul 03, 2008
Centocor Requests Approval From FDA of Golimumab for the Treatment of RA, Psoriatic Arthritis, and Ankylosing Spondylitis
Centocor submitted a Biologics License Application to the US FDA requesting the approval of golimumab, a human anti-TNFα monoclonal antibody, as a monthly subcutaneous treatment for adults with active forms of RA, PsA, and AS...
Friday May 16, 2008
Centocor Alerts Authorized Distributors and Prescribing Physicians About Stolen Infliximab (Remicade®)
A transport trailer carrying infliximab (Remicade®) was stolen en route to a specialty distributor on May 6, 2008...
Tuesday May 13, 2008
Incidence and Prevalence of Psoriatic Arthritis
Researchers found geographic variations in the occurrence of PsA, but methodological issues make interpreting epidemiologic data difficult…
Monday Apr 21, 2008
Abbott’s Humira® (adalimumab) Approved in Japan for the Treatment of RA
Abbott received approval in Japan for Humira® (adalimumab) to treat RA in patients with inadequate response to conventional therapy...
Friday Apr 04, 2008
Seven New Psoriasis Risk Genes Identified
A genome-wide study has identified 7 new genes that appear to increase a person's risk for psoriasis…
Tuesday Apr 01, 2008
Analysis of Contrast-Enhanced MRI of Hands and Wrists in Patients with Psoriatic Arthritis
Contrast-enhanced MRI demonstrates bone marrow edema, erosions, tendon and soft tissue disease, and median nerve involvement in patients with PsA of the hands and wrists…
Thursday Mar 27, 2008
Anacor’s Phase IIa Psoriasis Trial of AN2728 Achieves Primary, Secondary Endpoints
Anacor Pharmaceuticals, Inc announced positive results from a phase IIa clinical trial of AN2728, a boron-containing inhibitor of phosphodiesterase-4 (PDE4), in patients with psoriasis...
Wednesday Mar 19, 2008
Centocor, Schering-Plough Submit Marketing Authorization Application Requesting EU Approval of Golimumab to Treat RA, PsA, AS
Centocor, Inc and Schering-Plough Corp are seeking EU approval of golimumab, which targets and neutralizes both the soluble and membrane-bound forms of TNFα, to treat RA, PsA, and AS...
Thursday Feb 21, 2008
Computer-Assisted Validation of the Synovitis Score
Researchers assessed the reliability of the synovitis score as a grading system for chronic joint diseases...
Thursday Feb 14, 2008
Celgene Reports More Positive Phase II Data on Apremilast in Psoriasis Patients; to Expand Dosing Level, Duration; Accelerate Advancement in Psoriasis, Psoriatic Arthritis, RA
Celgene Corp announced positive clinical data from a phase II study of apremilast (CC-10004), its lead orally bioavailable, small molecule inhibitor of TNF/PDE4, in patients with moderate-to-severe plaque psoriasis...
Friday Feb 08, 2008
TNF Inhibitors, Efalizumab, Alefacept Herald New Era in Psoriasis Treatment
New treatment strategies that include TNF-α inhibitors, efalizumab, and alefacept offer better psoriasis control with less toxicity, but still need to be compared with traditional agents in clinical trials...
Monday Feb 04, 2008
Amgen, Wyeth Report Enbrel® (etanercept) Significantly Reduced Levels of CRP, a Marker of Inflammation, in Patients with Moderate-to-Severe Plaque Psoriasis
Amgen Inc and Wyeth Pharmaceuticals announced findings from a retrospective analysis demonstrating that Enbrel® (etanercept), a fully human soluble TNF receptor, reduced C-reactive protein (CRP) in patients with moderate-to-severe plaque psoriasis...
Wednesday Jan 23, 2008
Abbott's Humira® Approved in US for Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
Abbott Laboratories announced it has received US FDA approval to market Humira® (adalimumab) for adults with moderate-to-severe chronic plaque psoriasis...
Wednesday Jan 16, 2008
Etanercept Clears Plaque Psoriasis in Children and Adolescents
Etanercept (Enbrel®) safely reduces disease severity in children and adolescents with moderate-to-severe plaque psoriasis, and improvements are evident as early as the second week of therapy...
Tuesday Jan 15, 2008
Three More Cases of Significant Neutropenia Lead to Recommendation for Routine CBC Monitoring
Three more cases of significant neutropenia in rheumatoid arthritis (RA) and psoriatic arthritis patients treated with etanercept lead to a recommendation for regular monitoring of complete blood counts (CBC)...
Monday Jan 07, 2008
Abbott's Humira® Approved in the EU for Treatment of Moderate-to-Severe Plaque Psoriasis
Abbott announced it has received marketing authorization from the European Commission for the use of the TNF antagonist Humira® (adalimumab) as a treatment for moderate-to-severe plaque psoriasis. Humira is the first fully human, self-injectable biologic for the treatment of psoriasis...
Tuesday Nov 13, 2007
Anti-IL-12/23 Monoclonal Produces Dramatic Results in Psoriatic Arthritis
The anti-IL-12/23 monoclonal antibody ustekinumab produced dramatic, durable improvements in psoriatic arthritis, according to phase II data reported at the American College of Rheumatology...
Friday Nov 09, 2007
Efalizumab Suspected of Triggering Arthritis in Subset of Psoriasis Patients
A small subset of patients treated with efalizumab for severe plaque psoriasis developed new-onset psoriatic arthritis...
Thursday Nov 08, 2007
Centocor, Schering-Plough's Anti-TNF Golimumab Significantly Improved Articular, Skin, and Nail Manifestations in Patients With Psoriatic Arthritis in Phase III Study; Met Primary and Major Secondary Endpoints
Centocor, Inc, a wholly owned subsidiary of Johnson & Johnson, announced that patients with active psoriatic arthritis (PsA) receiving monthly subcutaneous injections of golimumab experienced significant and sustained improvements in the joint and skin manifestations of the disease, according to findings from the largest phase III biologic study (GO-REVEAL trial) in PsA subjects...
Thursday Nov 08, 2007
Centocor, Schering-Plough's Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of AS in Phase III Study; Monthly Treatment Yielded Marked Improvements in Physical Function
Centocor, Inc, a wholly owned subsidiary of Johnson & Johnson, announced that more than half of patients receiving monthly subcutaneous injections of golimumab 50 mg and 100 mg experienced significant and sustained improvements in the signs and symptoms of active ankylosing spondylitis (AS), according to the phase III study (GO-RAISE trial) results...
Friday Oct 19, 2007
Lilly Acquires Exclusive Rights to MacroGenics' Humanized Anti-CD3 Monoclonal Antibody and Will Collaborate to Develop Autoimmune Disease Treatments
Eli Lilly and Co and MacroGenics, Inc have entered into a global strategic alliance to develop and commercialize teplizumab (MGA031 or hOKT3γ1(Ala-Ala)), a humanized, non-Fc receptor binding, anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules, for use in the treatment of multiple T–cell-mediated autoimmune diseases...
Tuesday Sep 11, 2007
Synovio-Entheseal Complex Seen As Key to Psoriatic Arthritis, Spondylarthropathies
The synovio-entheseal complex (SEC), where the enthesis and synovium come together in a synovial joint, links joint damage and innate immune activation leading to joint inflammation...McGonagle D, et al. Arthritis Rheum. 2007;56:2482-2491.
Tuesday Aug 28, 2007
Systematic Review Finds No Benefit From Selenium or Vitamins A, C in Arthritis; Raises Methodological Questions About Studies Showing Benefit From Vitamin E
Antioxidant vitamins A, C, and E, sometimes combined with selenium, have been widely touted as beneficial for the treatment of arthritis, but a systematic review finds little convincing evidence of efficacy...
Thursday Aug 23, 2007
NICE Issues Positive Appraisal of Abbott's Humira® (adalimumab) for the Treatment of Psoriatic Arthritis in UK Patient Population
The National Institute for Health and Clinical Excellence has published final guidance on the use of Humira® (adalimumab, Abbott Laboratories), a recombinant human monoclonal antibody that binds specifically to TNF-a, for the treatment of psoriatic arthritis (PsA)...
Wednesday Aug 22, 2007
PsA Patients May Benefit From Statin Therapy
New research linking PsA with subclinical atherosclerosis may point to a potential role for statin therapy in these patients…Gonzalez-Juanatey C, et al. Arthritis Rheum. 2007;57:1074-1080.
Thursday Aug 16, 2007
Welichem Initiates Phase I Clinical Trial of Topical Cream in Patients With Mild-to-Moderate Psoriasis
Welichem Biotech Inc, a publicly-traded biotechnology company developing therapeutic drugs in the fields of autoimmune diseases and cancer, announced the initiation of a phase I clinical trial of its antipsoriasis candidate WBI-1001, a small synthetic molecule compound originally isolated from bacterial metabolites, and formulated as a topical treatment...
Monday Aug 13, 2007
Can B-Cell Depletion With Rituximab Trigger Psoriasis?
New case studies linking rituximab therapy for RA and SLE with new-onset psoriasis may call for caution on the ever-expanding use of the B-cell depleting drug...Dass S, et al. Arthritis Rheum. 2007;56:2715-2718.
Tuesday Jul 31, 2007
Barrier Therapeutics Announces Positive Phase IIb Data With Oral Rambazoleâ„¢ in Moderate-to-Severe Plaque Psoriasis
Barrier Therapeutics, Inc, announced positive results from its phase IIb dose-finding study of oral Rambazoleâ„¢, an investigational all-trans retinoic acid (ATRA) metabolism blocking agent drug candidate, for moderate-to-severe plaque psoriasis.
Monday Jun 11, 2007
Centocor's Remicade® (Infliximab) Receives EU Approval as First and Only Biologic for the Treatment of Pediatric Patients With Severe, Active Crohn's Disease
Centocor, Inc, a wholly owned subsidiary of Johnson & Johnson and Schering-Plough Corp, announced that the European Commission has approved a new indication for Remicade (infliximab) allowing for the treatment of severe, active Crohn's disease (CD) in pediatric patients ages 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator, and primary nutrition therapy, or who are intolerant to, or have contraindications for such therapies...
Monday Jun 11, 2007
Abbott's HUMIRA® (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
Abbott Laboratories announced that it has received marketing authorization from the European Commission for the use of Humira® (adalimumab) as a treatment for severe Crohn's disease (CD)...
Tuesday Jun 05, 2007
Peptech's Anti-TNF Domain Antibody (PN0621) Enters Phase I Clinical Trial
Peptech Limited, is a clinical-stage biopharmaceutical company dedicated to developing and providing antibody- and peptide-based human therapeutic products for the treatment of inflammatory diseases and cancer...
Friday May 25, 2007
Accumulating Evidence Supports Adalimumab for Severe Psoriatic Arthritis
Adalimumab (Humira®) is safe and effective for patients with active psoriatic arthritis (PsA) who showed an inadequate response to disease-modifying antirheumatic drugs (DMARDs)...
Wednesday May 23, 2007
Celgene to Advance Clinical and Regulatory Development of Oral Anti-Inflammatory Agents Based on Successful Phase II Trial in Psoriasis; Expands Clinical Program to Include RA and PsA
Celgene Corp (SUMMIT, New Jersey), an integrated global biopharmaceutical company engaged in the discovery, development, and commercialization of novel therapies for the treatment of inflammatory diseases and cancer, announced plans to advance its leading oral anti-inflammatory candidates to address a broad range of inflammatory diseases...
Monday Apr 16, 2007
Abbott Seeks US and EU Regulatory Approval for HUMIRA® (Adalimumab) in Psoriasis; Receives US FDA Approval in Crohn's Disease
Abbott Laboratories announced that it has simultaneously submitted a supplemental Biologics License Application (sBLA) with the US FDA and a Type II Variation to the European Medicines Agency (EMEA) seeking approval to market HUMIRA® (adalimumab) as a treatment for moderate-to-severe chronic plaque psoriasis, the fifth autoimmune disease targeted for HUMIRA therapy in both the US and Europe...
Thursday Apr 05, 2007
More Evidence Points Toward Safety of Anti-TNF Drugs During Pregnancy
Three recent case reports add to an accumulating body of evidence that the TNF-blockers are safe during pregnancy, but one new report is far from the final word on the issue...
Wednesday Apr 04, 2007
Repeated B-Cell Depletion Safe, Effective Over 5 Years in RA
B-cell depletion with rituximab was effective for an average of 15 months per cycle and was relatively well tolerated for up to 5 repeat cycles in patients with otherwise refractory RA...
Tuesday Apr 03, 2007
Inflammation More Important Than Joint Damage in Psoriatic Arthritis Disability
Psoriatic arthritis disease activity is more important than joint damage in causing disability, especially in the early years of disease duration…
Wednesday Mar 07, 2007
Evotec and Interprotein Sign Collaboration Agreement to Develop Small Molecule Interleukin-6 Inhibitors to Treat Inflammatory Diseases
Evotec AG, a leader in the discovery and development of small molecule drugs, and Interprotein Corporation, a developer of orally bioavailable small molecule drugs that modulate protein-protein interactions, announced that they have signed a collaboration agreement on Interprotein's interleukin-6 (IL-6) inhibitors program for the development of novel, orally active drugs for the treatment of inflammatory diseases...
Wednesday Feb 28, 2007
Abbott's HumiraR (Adalimumab) Receives FDA Approval for Self-Administered Treatment of Moderate-to-Severe Crohn's Disease; Represents 4th FDA Approval in Immune-Mediated Diseases for Humira
Abbott announced it has received US FDA approval to market Humira® (adalimumab, a fully human anti-TNF-α monoclonal antibody) as a treatment for reducing the signs and symptoms and inducing and maintaining clinical remission of moderately-to-severely active Crohn's disease (CD) in adults who have had an inadequate response to conventional therapy...
Wednesday Dec 20, 2006
Celera Identifies Genetic Variations in Genes Encoding IL-12 and IL-23 Predisposing Individuals to Increased Risk for Psoriasis
Celera, an Applera Corporation business, announced findings that variants in the genes encoding interleukin-12 (IL12B) and interleukin-23 (IL23R), involved in regulating the behavior of cells of the immune system, independently contribute to psoriasis risk.
Monday Nov 20, 2006
Cytochroma Initiates Phase II Psoriasis Clinical Trial for CTA018, a Novel Vitamin D Analog
Cytochroma Inc, an integrated specialty pharmaceutical company engaged in the development and commercialization of proprietary products related to vitamin D deficiency and novel vitamin D therapies to treat hyperproliferative disorders such as psoriasis and cancer, has initiated the recruitment of patients with chronic plaque psoriasis for a phase II clinical trial with CTA018 cream.
Thursday Nov 16, 2006
Abbott's HUMIRA (adalimumab) Approved in Canada for Treatment of Ankylosing Spondylitis
Abbott announced that it has received approval from Health Canada to market HumiraR (adalimumab) as a treatment for active ankylosing spondylitis (AS) in Canada.
Thursday Oct 19, 2006
Access to TNF-Blockers Severely Limited in UK
Access to TNF-inhibitor treatment is limited even for British RA patients who meet official guidelines for treatment, and is even more limited for patients with psoriatic arthritis or ankylosing spondylitis ... Kay, LJ, et al. Rheumatology. 2006 Oct 11; [Epub ahead of print].
Friday Sep 29, 2006
Amgen to Acquire Avidia Including Its Phase I Clinical Stage Interleukin-6 Inhibitor and Novel Avimer Protein Platform
Amgen announced that it has entered into a definitive merger agreement under which Amgen has agreed to acquire Avidia, a privately held biopharmaceutical company located in Mountain View, Calif., that discovers and develops a new class of human therapeutic known as Avimerâ„¢ (from avidity multimers) proteins.
Thursday Sep 21, 2006
Avidia Initiates Clinical Trial of Avimerâ„¢ C326, an Inhibitor of Interleukin-6, for Crohn's Disease
vidia, Inc., a privately-held biopharmaceutical company focused on discovering and developing a new class of small, assembled human therapeutic proteins called Avimersâ„¢ (from avidity multimers), announced that it has initiated dosing of the first patient for a phase I clinical trial of its Avimer drug candidate C326, an inhibitor of interleukin-6 (IL-6), for the treatment of Crohn's disease.
Wednesday Sep 13, 2006
Can-Fite BioPharma to Develop Its A3 Adenosine Receptor Agonist (CF101) for Psoriasis
Can-Fite BioPharma, a clinical-stage drug development company focused on a portfolio of orally bioavailable, highly selective, small-molecule A3 adenosine receptor (A3AR) agonists with potent activities in inflammation and cancer, announced the intent to initiate a phase II clinical trial in psoriasis for its lead drug candidate, CF101.
Monday Sep 11, 2006
Small, Portable In-Office MRI Can Monitor Response to Therapy in RA
As RA treatments become more effective and expensive, monitoring response to therapy becomes more important. Two new studies suggest that small, portable MRI devices might help...
Monday Sep 11, 2006
Abbott Seeks US and EU Approvals for HUMIRA (Adalimumab) for Crohn's Disease
Abbott announced it has simultaneously submitted a supplemental Biologics License Application with the US FDA and a Type II Variation to the European Medicines Agency seeking approval to market HUMIRAR (adalimumab) as a treatment for moderate-to-severe Crohn's disease...
Tuesday Aug 15, 2006
Centocor's REMICADE Receives Expanded Psoriatic Arthritis Indication
Centocor, Inc. announced that the US FDA has expanded marketing approval for Remicade® (infliximab) to inhibiting the progression of structural damage and improving physical function in patients with active psoriatic arthritis (PsA), in addition to reducing the signs and symptoms of active arthritis.
Tuesday Aug 01, 2006
Schering-Plough's REMICADE Receives EU Approval as Monotherapy for Treatment of Psoriatic Arthritis; Abbott's HUMIRA Receives FDA Approval for Treatment of Ankylosing Spondylitis
Schering-Plough Corporation announced that the European Commission approved the use of REMICADE® (infliximab) as monotherapy in the treatment of active and progressive psoriatic arthritis (PsA) in patients who show intolerance to methotrexate (MTX) or for whom MTX is contraindicated.
Friday Jul 28, 2006
Serono Initiates First Large-Scale European Pharmaco-Epidemiologic Study to Gather Additional Safety Data on RaptivaR in Psoriasis
Serono announced that it has initiated a prospective 7-year cohort, multi-national, multicenter study in more than 7000 adult patients with moderate-to-severe plaque psoriasis who have been treated with RaptivaR (efalizumab).
Tuesday Jun 27, 2006
Abbott Receives FDA Approval for New HUMIRA® Injection Device
Abbott Laboratories announced that the US FDA approved the HUMIRA® Pen, a new single-use, disposable, pen-like device for administering HUMIRA, a treatment approved in the US for moderate-to-severe rheumatoid arthritis and for active psoriatic arthritis....
Saturday Jun 24, 2006
Experts to Issue Psoriatic Arthritis Remission Guidelines
PsA remission now in our sights, say IMPACT trial investigators at the EULAR 2006 meeting... Kavanaugh A, et al. EULAR 2006 Meeting; June 21–24, 2006; Amsterdam, the Netherlands. Abstract OP0104.
Monday Jun 12, 2006
Abbott's Humira® Approved in European Union for Severe Ankylosing Spondylitis
Abbott Laboratories announced that Humira® (adalimumab) was approved by the European Commission for marketing in Europe as a treatment for severe, active ankylosing spondylitis...
Monday Jun 05, 2006
PsA Enthesopathy As Cause of Plantar Fasciitis Responds to TNF Inhibitors
The TNF inhibitors infliximab and etanercept are both effective for the treatment of enthesopathy associated with psoriatic arthritis... Ritchlin CT. J Rheumatol. 15 May 2006; [Epub ahead of print]
Wednesday May 24, 2006
Centocor's RemicadeR Approved by US FDA for Pediatric Crohn's Disease
Centocor Inc announced US FDA approval of Remicade® (infliximab) for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active Crohn's disease...
Wednesday May 17, 2006
Manhattan Pharmaceuticals Delays Phase IIa Trial of Topical PTH (1-34) for Psoriasis
Manhattan Pharmaceuticals, Inc, of New York, NY, announced a delay in the phase IIa dosing study of topical PTH (1-34) for psoriasis...
Wednesday May 17, 2006
Avidia Raises $43.8 Million in Series C Financing to Advance Its Lead Avimerâ„¢ Drugs for Inflammation and Autoimmune Diseases
Avidia, Inc, announced that it has raised $43.8 million in a Series C financing round...
Monday May 08, 2006
Additional Neuropathies Linked to TNF Inhibitors
Guillain-Barré syndrome, demyelinating and axonal neuropathies, and a central nervous system syndrome have been reported recently in patients treated with TNF inhibitors... Shin I-SJ, et al. Arthritis Rheum. 2006;54:1429-1434; Jarand J, et al. J Rheumatol. 2006;33:1018-1020.
Thursday May 04, 2006
Adding Alefacept Increases MTX Response in Psoriatic Arthritis
Alefacept plus methotrexate significantly increased response rates in patients with psoriatic arthritis... Mease PJ, et al. Arthritis Rheum. 2006;54:1638-1645.
Monday May 01, 2006
Abbott's HumiraR (Adalimumab) Receives Positive Opinion From EMEA for Ankylosing Spondylitis
Abbott Laboratories, of Abbott Park, Illinois, announced that the Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMEA), issued a positive opinion recommending approval of Humira® (adalimumab)...
Tuesday Apr 11, 2006
Leflunomide is an Effective Treatment for Psoriatic Arthritis (PsA) and Plaque Psoriasis
Once-daily oral leflunomide is a safe and effective treatment for psoriatic arthritis (PsA) and plaque psoriasis... Nash P, et al. Dermatology. 2006;212:238-249.
Monday Mar 27, 2006
RemicadeR Approved in Australia for the Treatment of Early RA and Psoriatic Arthritis
Schering-Plough Corporation, of Kenilworth, New Jersey, announced that the Therapeutic Goods Administration of the Department of Health and Ageing in Australia has revised the indication of Remicade® (infliximab)...
Monday Mar 06, 2006
Phase III Data for Centocor's Remicade® Show Rapid and Marked Improvement in Moderate to Severe Plaque Psoriasis
Centocor, Inc, of Horsham, Pennsylvania, announced the results from its phase III EXPRESS II study of Remicade® (infliximab)...
Monday Feb 13, 2006
QuatRx Files for $86.25 Million IPO, Seeks Partner for Phase IIb Trial of Vitamin D Analogue for Psoriasis
QuatRx Pharmaceuticals Co of Ann Arbor, Michigan, announced that it has filed a registration statement with the US Securities and Exchange Commission...
Friday Feb 03, 2006
Seal Oil May Lead to Subjective Improvements in Psoriatic Arthritis
Seal oil, rich in omega-3s, may improve psoriatic arthritis patients' global assessment of their disease, suggesting a trend toward a decrease in the number of tender joints, possibly due to seal oil's anti-inflammatory effects... Madland TM, et al. J Rheum. 2006;33:307-10.
Monday Jan 30, 2006
Sales of Abbott's Humira® Exceed $1B in 2005
Abbott Laboratories reported that worldwide sales for Humira® (adalimumab) reached $1.4 billion...
Wednesday Jan 25, 2006
Targeted Genetics Restructures to Advance Anti-TNF-Alpha Agent tgAAC94 for Inflammatory Arthritis
Targeted Genetics Corporation, of Seattle, Washington, announced the restructuring of its operations...
Wednesday Jan 11, 2006
Manhattan's PTH 1-34, a Topical Treatment for Psoriasis, Enters Phase IIa Trials
Manhattan Pharmaceuticals, Inc, of New York City, announced the initiation of a phase IIa clinical study of PTH 1-34, a parathyroid hormone-related peptide analog, for the topical treatment...
Thursday Dec 22, 2005
Studies Evaluate Relationship Between Smoking, Obesity, and Exacerbation of Psoriasis
New research into the behavioral and environmental determinants of psoriasis has linked obesity and smoking with exacerbation of the disease, calling attention to the importance of weight reduction and smoking cessation in such patients…Fortes C, et al. Arch Dermatol. 2005;141:1580-1584.
Wednesday Nov 02, 2005
Additional Encouraging Data from Targeted Genetics' Inflammatory Arthritis Program
The trial was designed to evaluate the safety of a single dose of tgAAC94...
Tuesday Nov 01, 2005
CAT and Abbott Resolve Royalty Dispute Regarding Humira®
Cambridge Antibody Technology Group PLC (CAT), a British biotechnology company headquartered in Cambridge, England, and Illinois-based Abbott Laboratories have reached an agreement...
Monday Oct 31, 2005
Meta-Analysis Points to the Need to Customize Treatment for Subtypes of Juvenile Idiopathic Arthritis
With the increased recognition that radiologic joint and cartilage damage occurs earlier in the course of juvenile idiopathic arthritis than originally thought, a recently released literature review underlines the importance of taking a customized approach to treatment of the disease. However, despite treatment advances, researchers argue that there is no evidence-based consensus on the optimal treatment regimen for several subtypes of JIA. Hashkes PJ, Laxer RM. JAMA. 2005;294:1671-1684.
Monday Oct 17, 2005
Infliximab Found Highly Effective for Skin and Nail Psoriasis
Infliximab (Remicade®) monotherapy shows rapid onset of action and sustained efficacy as both induction and maintenance therapy for patients with moderate-to-severe skin and nail psoriasis, according to the results of a new multicenter Phase III study ... Reich K, et al. Lancet 2005;366:1367-1374.
Wednesday Oct 12, 2005
Centocor Obtains Approval in Europe for Remicade® for Psoriasis
Centocor, Inc, and its marketing partner, Schering-Plough Corporation, have announced that the European Commission has granted approval of RemicadeR (infliximab)...
Thursday Oct 06, 2005
Abbott's HumiraR (Adalimumab) Approved in Europe for Psoriatic Arthritis and Severe Rheumatoid Arthritis
Abbott Laboratories announced that it has received US Food and Drug Administration (FDA) approval to market HumiraR (adalimumab)...
Wednesday Sep 28, 2005
New-Onset or Exacerbation of Psoriatic Skin Lesions in RA Patients on Tumor Necrosis Factor-Alpha Antagonists
Nine rheumatic arthritis (RA) patients treated with 3 different tumor necrosis factor-alpha (TNF-α) antagonist formulations developed new-onset or an exacerbation of psoriatic lesions, despite the efficacy of TNF-α antagonists in treating such psoriatic lesions in the past. These first-ever reported cases will likely spur further analysis of the unexpected phenomenon...Kary S, et al. Ann Rheum Dis. Online First. September 8, 2005.
Wednesday Sep 21, 2005
Johnson & Johnson's Remicade (infliximab) First Biologic Approved by US FDA for Treatment of Ulcerative Colitis
Centocor, Inc, a biotech unit of Johnson & Johnson, has announced that Remicade® (infliximab) has been approved by the US Food and Drug Administration...
Monday Aug 15, 2005
Abbott's Humira Approved in Europe for Psoriatic Arthritis and Early RA
Abbott Laboratories has received approval from the European Commission to market HumiraR...
Tuesday Aug 02, 2005
Etanercept Does Not Increase Risk of Squamous Cell Carcinoma in RA Patients
Unlike cyclosporine, etanercept does not appear to increase risk of skin cancer in rheumatoid arthritis (RA) patients... Lebwohl M, et al. Arch Dermatol. 2005;141:861-864.
Wednesday Jun 15, 2005
Alefacept in Combination With Methotrexate Evaluated for the Treatment of Psoriatic Arthritis
A 6-month study of the memory T cell suppressor alefacept suggests that the agent will be an effective tool in the armamentarium against PsA... Presented at: Annual European Congress of Rheumatology of EULAR; June 8-11, 2005; Vienna, Austria.
Wednesday Jun 15, 2005
Etanercept Expands PsA Indication to Include Improvement of Physical Function
Amgen Inc and Wyeth Pharmaceuticals announced that the US Food and Drug Administration (FDA) expanded the marketing approval of Enbrel® (etanercept) to include the improvement of physical function in patients with psoriatic arthritis (PsA).
Thursday Jun 09, 2005
Abatacept Inhibits Structural Damage in RA Patients with Inadequate Response to Methotrexate
New studies help define and clarify potential niche for costimulation blockade in autoimmunity...Presented at: Annual European Congress of Rheumatology of EULAR; June 8-11, 2005; Vienna, Austria.
Friday May 20, 2005
Study Provides Clues to the Mechanism of Remission of Inflammatory Diseases During Pregnancy
Analysis of pro- and anti-inflammatory cytokines in pregnant women with rheumatoid arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis may help provide a better understanding as to why certain rheumatic diseases improve during pregnancy...Ostensen M, et al. Ann Rheum Dis. 2005;64:839-844
Tuesday May 17, 2005
Infliximab Approved for Treatment of Psoriatic Arthritis
Infliximab joins etanercept as an anti-TNF-α treatment option for patients with active psoriatic arthritis...FDA approves Remicade® for ninth indication: psoriatic arthritis [press release]. Malvern, Pa: Centocor, Inc; May 17, 2005.
Monday Mar 07, 2005
Latest Trial Results for Biologics in Psoriatic Arthritis
Highlighted results from the American Academy of Dermatology meeting confirm the efficacy of anti-TNF therapy in treating psoriatic arthritis...63rd Annual Meeting of the American Academy of Dermatology, February18-22, 2005; New Orleans, La.
Thursday Feb 17, 2005
Anti-CCP Antibodies Detected in Psoriatic Arthritis Patients
New research suggests that the specificity of this marker may lead to more precise diagnostic criteria for this broad spectrum disease...Vander Cruyssen B, et al. Ann Rheum Dis. 2005. [Epub ahead of print]
Thursday Feb 03, 2005
Crohn's Disease Patients With Attenuated Response to Infliximab May Respond to Adalimumab
Mimicking the paradigm seen with TNF-blockade in rheumatoid arthritis, preliminary data suggest that switching infliximab nonresponders to adalimumab may improve the clinical response and reduce disease activity...Papadakis KA. Am J Gastroenterol. 2005;100:75-79.
Monday Dec 13, 2004
Synovial Tissue Interleukin-18 Expression Correlates With Inflammatory Arthritis Disease Activity
New study underscores the important proinflammatory role of IL-18 in the pathophysiology of inflammatory arthritis, and suggests that treatment that inhibits or neutralizes endogenous IL-18 may become an effective tool in controlling synovial tissue inflammation&Rooney T, et al. Ann Rheum Dis. 2004;63:1393-1398.
Wednesday Oct 27, 2004
Anti-TNF Drugs Appear to Show Benefits in Most Ankylosing Spondylitis Patients and May Also Improve Psoriatic Arthritis
Recent study findings indicate that ankylosing spondylitis and psoriatic arthritis may respond well to infliximab, etanercept, and adalimumab... Rudwaleit M, Sieper J… Z Rheumatol. 2004;63:193-202.
Wednesday Oct 27, 2004
Anti-TNF Drugs Appear to Show Benefits in Most Ankylosing Spondylitis Patients – and May Also Improve Psoriatic Arthritis
Recent study findings indicate that ankylosing spondylitis and psoriatic arthritis may respond well to infliximab, etanercept, and adalimumab... Rudwaleit M, Sieper J… Z Rheumatol. 2004;63:193-202.
Friday Oct 22, 2004
Research Shows Benefits of TNF-α Blockers in Treating Ankylosing Spondylitis
Studies involving etanercept, infliximab, and adalimumab consistently show long-term benefits with regard to disease activity, function, and spinal mobility... Davis JC, et al. Presented at: Annual Meeting of the American College of Rheumatology; October 20, 2004; San Antonio, Tex.
Friday Oct 22, 2004
Research Shows Benefits of TNF-α Blockers in Treating Ankylosing Spondylitis
Studies involving etanercept, infliximab, and adalimumab consistently show long-term benefits with regard to disease activity, function, and spinal mobility... Davis JC, et al. Presented at: Annual Meeting of the American College of Rheumatology; October 20, 2004; San Antonio, Tex.
Friday Oct 22, 2004
Infliximab Therapy Markedly Improves Skin Symptoms in Psoriatic Arthritis
Independent of the arthritis response, clinicians should continue to use the anti-tumor necrosis factor agent infliximab for patients with active psoriatic arthritis because the drug markedly reduces skin symptoms... Mease P, et al. Presented at: Annual Meeting of the American College of Rheumatology; October 20, 2004; San Antonio, Tex.
Wednesday Oct 20, 2004
Adalimumab Markedly Reduces Psoriatic Arthritis Symptoms
Striking benefits are shown for psoriatic arthritis patients' skin and joint symptoms with adalimumab vs placebo... Mease PJ, et al. Presented at Annual Meeting of the American College of Rheumatology; October 19, 2004; San Antonio, Texas
Wednesday Aug 18, 2004
Study Shows that Etanercept (EnbrelR) Reduces Joint Symptoms, Improves Psoriatic Lesions, and Inhibits Radiographic Progression in Patients with Psoriatic Arthritis
In a study described in the July issue of Arthritis and Rheumatism, Mease and colleagues found that etanercept significantly improved the clinical symptoms and skin lesions of psoriasis in patients with psoriatic arthritis. (Mease PJ, et al. Arthritis Rheum. 2004;50:2264-2272.)
Wednesday Jul 14, 2004
Mycobacterial Vaccine Less Effective than Immunotherapies in Treatment of PSA
|
